- Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management 
and other VCs in oversubscribed funding round to accelerate Turn Bio's 
preclinical advances in multiple therapeutic areas

Turn Biotechnologies, a cell rejuvenation company developing novel mRNA 
medicines to cure untreatable, age-related conditions, today announced that it 
closed an oversubscribed fundraising round to support the next stage of its 
development.

Investments from two international pharmaceutical organizations and a venture 
capital group associated with a third underscored widespread interest in Turn 
Bio's unique cell rejuvenation therapy, which is built on the company's 
proprietary ERA™ platform.

International pharmaceutical industry backing came from three groups:

    -- Astellas Venture Management LLC, a venture capital organization within 
       Astellas Pharma, which is actively engaged in business as an 
       R&D-driven global pharmaceutical company with the business philosophy 
       to "Contribute toward improving the health of people around the world 
       through the provision of innovative and reliable pharmaceutical 
       products";
    -- Daewoong Pharmaceutical, recognized as one of the world's most 
       collaborative pharmaceutical companies; and
    -- HanAll Biopharma, which is conducting innovative research in 
       ophthalmology, immunology, oncology, neurology, and produces 
       therapeutics in endocrine, circulatory and urological diseases.

"The attention and support Turn Bio is receiving from organizations around the 
world shows the confidence companies have in our ability to utilize our 
proprietary technology platforms to develop cures for now-untreatable 
conditions that afflict millions of people globally," said CEO Anja Krammer. 
"Turn Bio is closer to proving that cell rejuvenation will transform how 
medicine treats human disease – and ultimately extends the human healthspan."

An executive from HanAll acknowledged the importance of Turn Bio's work.

"Many age-related diseases have long been significant areas of unmet patient 
need," said Dr. Almira Chabi, chief medical officer and chief development 
officer at HanAll Pharmaceutical International, a U.S. organization HanAll 
created to strengthen its R&D. "Turn Bio's innovative platform may bring a 
pivotal transformation to a wide array of therapeutic areas. HanAll is 
committing support and investment to help realize the full potential of this 
pioneering technology as Turn Bio advances to a new phase of growth."

The round also attracted investment from LongeVC, which is focused on 
accelerating companies' development in the longevity space; ThreeD Capital, 
which invests in disruptive technologies, and Vitality Healthspan Foundation. 
Existing investors, Methuselah Fund, Formic Ventures and Shanda Group, 
increased their investments this round.

ABOUT TURN BIOTECHNOLOGIES 

Turn Bio is a pre-clinical-stage company focused on repairing tissue at the 
cellular level. The company's proprietary mRNA platform technology, ERA™, 
restores optimal gene expression by combatting the effects of aging in the 
epigenome. This restores the cells' ability to prevent or treat disease, and 
heal or regenerate tissue and will help to fight incurable chronic diseases.

The company is currently completing pre-clinical research on tailored therapies 
targeting indications in dermatology and immunology, as well as developing 
therapies for ophthalmology, osteo-arthritis and the muscular system. For more 
information, see www.turn.bio.

FOR MORE INFORMATION, CONTACT:

Jim Martinez, rightstorygroup
jim@rightstorygroup.com or (312) 543-9026

SOURCE  Turn Biotechnologies